Authors: Kamphuis AEM, Mujuru HA, Bwakura-Dangarembizi MF, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Salvadori N, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Burger DM, for the UNIVERSAL1 Trial Team. Presented at: CROI 2026 [button...
Publications
Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials
Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White...
Optimising Paediatric HIV Treatment: Recent Developments and Future Directions
Authors: Kamphuis A.E.M., Bamford A., Tagarro A., Cressey AT, Bekker A, Amuge P, Mujuru HA, Ndongo AF, Diack A, Compagnucci A, Lallemant M, Colbers A, Turkova A. Published in: Pediatric Drugs [button link="https://link.springer.com/article/10.1007/s40272-024-00656-4"...
Relative bioavailability of dolutegravir (DTG) and emtricitabine/tenofovir alafenamide fumarate (F/TAF) administered as paediatric tablet formulations in healthy volunteers
Authors: Bevers LAH, Kamphuis AEM, van der Wekken-Pas LC, Leisegang R, Lewis L, Burger DM, Colbers A Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 [button...